S&P 500 climbs to record high as in-line inflation data point to Fed rate cut
Romeo R. Dizon, Chief Financial Officer of Iridex Corp (NASDAQ:IRIX), reported purchasing shares of the company’s common stock on September 4, 2025. The transactions, representing the acquisition of shares, totaled $1531. The purchase comes as the medical technology company, currently valued at $23.11 million, trades at $1.38 per share, down 21% year-to-date but showing strong momentum over the past three months.
Dizon acquired a total of 1125 shares in a series of transactions. The prices paid ranged from $1.32 to $1.39 per share. According to InvestingPro analysis, the stock is currently trading below its Fair Value, with 8 additional key insights available to subscribers. Following these transactions, Dizon directly owns 54,750 shares of Iridex Corp.
In other recent news, IRIDEX Corporation reported its second-quarter earnings for 2025, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of -$0.06, which was better than the anticipated -$0.09. Additionally, IRIDEX reported revenue of $13.6 million, exceeding the expected $13.1 million. These results highlight a stronger performance for the company in this period. There were no reports of mergers or acquisitions in the recent updates. Analyst firms have not issued any upgrades or downgrades for IRIDEX at this time. Investors might find the company’s ability to exceed earnings and revenue estimates noteworthy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.